Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32687166 | 0.81 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL13363110 | 0.77 | — | — | |
| SCHEMBL27190105 | 0.75 | — | — | |
| SCHEMBL11228086 | 0.74 | NEK2 (0.32) | — | |
| SCHEMBL20555604 | 0.73 | SIGMAR1 (0.56) | OPRM1SIGMAR1KCNH2 | |
| SCHEMBL670308 | 0.73 | LMNA (0.51) | KCNH2 | |
| SCHEMBL19096872 | 0.73 | — | — | |
| SCHEMBL2142153 | 0.71 | SLC6A2 (0.35) | — | |
| Acetic Acid SCHEMBL17319027 | 0.71 | — | — | |
| SCHEMBL20504475 | 0.70 | SIGMAR1 (0.59) | OPRM1SIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2023-05-16 | — | — | US | disclosed |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | ESTEVE PHARMACEUTICALS SA (ES) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11649248-B2 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885SIGMAR1 4/4885KCNH2 2970/4885 |
| US-20210115062-A1 | OXADIAZASPIRO COMPOUNDS FOR THE TREATMENT OF DRUG ABUSE AND ADDICTION | OPRD1, OPRM1, OPRK1 | OPRM1 2/4885SIGMAR1 4/4885KCNH2 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.